US20240426824A1
University of Texas System
A method of determining the likelihood that a subject with acute myeloid leukemia (AML) will respond to a treatment comprising a BCL-2 inhibitor is provided. The method comprises detecting the levels of protein biomarkers in abiological sample obtained from a human subject. Subjects determined to …